Infectious Enteritis Treatment Market Size Expected to Grow USD 403.92 Million | Growth, trends and forecasts (2022

0

NEW YORK, April 8, 2022 /PRNewswire/ — The infectious enteritis treatment market the value is expected to grow by $403.92 million, progress to a CAGR of 5.09% from 2021 to 2026according to the latest Technavio report.

Technavio has announced its latest market research report titled Infectious Enteritis Treatment Market by Route of Administration and Geography – Forecast and Analysis 2022-2026

The market is segmented by Route of administration (oral and injectable routes) and geography [North America, Europe, Asia, and Rest of World (ROW)]. Besides, increasing geriatric population in countries, such as Japan, Italyand the United States is notably driving the growth of the market, although factors such as side effects associated with the treatment of infectious enteritis can hinder the market.

Request a free sample report for more information with exact growth variance and annual growth rate

Infectious Enteritis Treatment Market Scope

Report cover

Details

Page number

120

Year of reference

2021

Forecast period

2022-2026

Growth momentum and CAGR

Accelerate at a CAGR of 5.09%

Market Growth 2022-2026

$403.92 million

Market structure

Fragmented

Annual growth (%)

3.52

Regional analysis

North America, Europe, Asia and Rest of the World (ROW)

Successful market contribution

North America at 37%

Main consumer countries

United States, Canada, Germany, United Kingdom and China

Competitive landscape

Leading companies, competitive strategies, scope of consumer engagement

Profiled companies

Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc . ., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc. and Viatris Inc.

Market dynamics

Parent Market Analysis, Market Growth Drivers and Barriers, Fast and Slow Growing Segment Analysis, COVID 19 Impact and Future Consumer Dynamics, Market Condition Analysis for the Forecast Period,

Customization overview

If our report does not include the data you are looking for, you can contact our analysts and customize the segments.

Infectious Enteritis Treatment Market 2022-2026: Segmentation

37% of market growth will come from North America during the forecast period. The United States and Canada are the main markets for the treatment of infectious enteritis in North America. The growth of the market in this region will be faster than the growth of the market in the rest of the world (ROW). The significant increase in foodborne illnesses in countries like the United States will facilitate the growth of the infectious enteritis treatment market by North America over the forecast period.

The growth of the infectious enteritis treatment market share by the oral segment will be significant during the forecast period. The rapid action of oral rehydration therapy on patients will drive the growth of the market targeted by this segment in the coming years. For example, zinc, in conjunction with ORS, has also been observed to be effective in reducing acute diarrhea by 15-25%.

Request a FREE sample to better understand the market share and contribution of various regions and segments

Increase in the geriatric population in countries such as Japan, Italyand the United States to drive the growth of the market

For example, according to the United Nations (UN) Department of Economic and Social Affairs, the population distribution of the geriatric population (people aged 65 or over) was 702.9 million in 2019, which will become 727 million in 2020. Similarly, the geriatric population in India will increase by 41% over the next decade to reach 194 million in 2031. This increase in the percentage of geriatric population globally increases the demand for healthcare-associated infection treatment globally, which will work as a driver for the geriatrics market. treatment of infectious enteritis during the forecast period.

Adverse Reactions Associated with Infectious Enteritis Treatment to Challenge Market Growth

Infectious enteritis causes diarrhea and associated fluid and electrolyte loss. Maldigestion and malabsorption are the dominant underlying pathophysiological mechanisms; therefore, intravenous therapy is more effective (at least initially) in correcting electrolyte imbalances and fluid loss compared to oral administration. Crystalloid and colloid fluids should be considered part of fluid therapy. However, sometimes treatment of infectious enteritis with these fluids or any other drugs such as penicillin, cephalosporin, antifolates or combinations of sulfonamides, nitroimidazole, glycopeptide and monobactam antibiotics would additionally lead to various side effects due to to the historical allergy of the patients. These factors are expected to negatively impact the growth of the market over the forecast period.

Download a free sample report for insights on drivers, trends and challenges that will help companies assess and develop growth strategies for 2022-2026

Our Infectious Enteritis Treatment Market report covers the following areas:

Infectious Enteritis Treatment Market 2022-2026: Vendor Analysis

The report analyzes the competitive landscape of the market and offers information about several vendors in the market including:

  • Abbott Laboratories

  • Almirall S.A.

  • cipla ltd.

  • Zydus Lifesciences Ltd.

  • F. Hoffmann La Roche Ltd.

  • Galderma SA

  • GlaxoSmithKline Plc

  • Hetero Healthcare Ltd.

  • Mayne Pharma Group Ltd.

  • Medimetriks Pharmaceuticals Inc.

  • Merck KGaA

  • Pfizer Inc.

  • Teva Pharmaceutical Industries Ltd.

  • Tolmar Pharmaceuticals Inc.

  • Viatris inc.

Additionally, the market is fragmented and publishers are deploying growth strategies such as geographic expansion, product portfolio expansion and product innovation to compete in the market.

Download our FREE sample report for supplier information with product offerings and news

Infectious Enteritis Treatment Market 2022-2026: Key Highlights

  • Market CAGR over the forecast period 2022-2026

  • In-depth information on the factors that will contribute to the growth of the infectious enteritis treatment market over the next five years

  • Estimation of the infectious enteritis treatment market size and its contribution to the parent market

  • Predictions on upcoming trends and changes in consumer behavior

  • The growth of the infectious enteritis treatment market

  • Market Competitive Landscape Analysis and Detailed Vendor Information

  • Comprehensive details of factors that will challenge the growth of the Infectious Enteritis Treatment Market vendors

Related reports:

Atherosclerosis Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026: The atherosclerosis therapeutics market share is expected to grow USD 3.44 billion from 2021 to 2026, and the market growth momentum will accelerate at a CAGR of 5.66%. For more exclusive research information: Download our FREE sample report

Plasma C1 Protease Inhibitors Market by Product and Geography – Forecast and Analysis 2022-2026: Plasma C1 Protease Inhibitors market share is expected to grow USD 1.7 billion from 2021 to 2026, and the market growth momentum will accelerate at a CAGR of 7.4%. For more exclusive research information: Download our FREE sample report

Contents:

1. Summary

2 Market landscape

3 Market sizing

4 Five forces analysis

5 Market Segmentation by Route of Administration

6 Customer Landscape

7 Geographic landscape

8 drivers, challenges and trends

9 Supplier Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialist analysts, Technavio’s reporting library consists of over 17,000 reports and counts, spanning 800 technologies, spanning 50 countries. Their customer base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market intelligence to identify opportunities in existing markets and potentials and assess their competitive positions in changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)

Technavio (PRNewsfoto/Technavio)

Quote

Quote

See original content to download multimedia: https://www.prnewswire.com/news-releases/infectious-enteritis-treatment-market-size-to-grow-by-usd-403-92-million-growth- trends-and-forecasts-2022—2026-301520202.html

SOURCETechnavio

Share.

Comments are closed.